MRI Imaging of Retromuscular Hernia Repair With CICAT Visible®

Sponsor
Algemeen Ziekenhuis Maria Middelares (Other)
Overall Status
Recruiting
CT.gov ID
NCT02460029
Collaborator
Duomed (Industry)
10
1
79
0.1

Study Details

Study Description

Brief Summary

The aim of this study is the visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromuscular incisional hernia repair with the visible CICAT mesh (Dynamesh®).

Condition or Disease Intervention/Treatment Phase
  • Other: Ventral hernia

Detailed Description

INTRODUCTION:

Repair of ventral hernias always involves a scientific discussion about placing the "optimal mesh", the "optimal" mesh position or the "optimal" fixation method of the mesh. Today, there are a lot of meshes available of different materials, different textures, in different sizes and with different properties. The choice of the "right" mesh strongly depends on the sort of hernia and on the choice of the surgeon.

Furthermore, it is known that the majority of implanted meshes shrink to an extent, which may be of disadvantage for the patient. This has already been demonstrated in several animal studies, but clinical information on the mesh shrinkage is rare and mostly a result from revised surgery.

Most meshes for repair of abdominal hernia defects, based on polymeric textile, are invisible to conventional imaging techniques, inclusive "magnetic resonance imaging" (MRI). The textile company FEG Textiltechnik GmbH, Germany, has developed a unique method which allows imaging of the mesh in vivo in the MRI. For this purpose, these unique meshes contain an amount of iron particles. The particles are incorporated into the filaments, which are subsequent warp knitted to the mesh structure.

In a similar setting, the IMAP study, the visibility of the IPOM® mesh up to 13 months after laparoscopic ventral hernia repair will be investigated. Preliminary results from this study have shown a clear visibility and a promising outcome using this mesh.

PURPOSE:

The aim of this study is the visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromuscular incisional hernia repair with the visible CICAT mesh (Dynamesh®).

The investigators want to show that with this type of mesh it is possible to visualize the mesh after retromuscular placement in vivo in a safe manner.

Furthermore, the positioning of the mesh, mesh shrinkage or mesh shifting will be monitored with this technique. This provides long-term benefit and provides early treatment possibilities in case of post-operative complications related to the mesh position. Furthermore, by means of dynamic MRI measurements the mesh elasticity will be evaluated in both directions longitudinal as well as transversal.

These results will provide information about the degree of mesh incorporation and the mechanical behavior of the tissue-mesh compound.

PROCEDURES

Hernia Repair:
  • Introduction of the visible CICAT mesh (Dynamesh®) via laparotomy and retromuscular positioning of the mesh with a minimum overlap with the hernia defect of at least 5 cm in all directions.

  • All patients will receive a standardized pain treatment protocol. Analgesics used will be checked. Visual analog scale (VAS) for pain will be measured at 4 hours, 8 hours, 12 hours, 16 hours, 20 hours and 24 hours post-operatively and every 12 hours thereafter until discharge of the patient.

  • Pain medication after discharge will be monitored and checked with the patient at each consultation.

Clinical follow-up evaluation of all patients will be performed by the principal investigator.

MRI measurement will be performed at 1 and 13 months post-operatively.

MRI scan method:

Used gear: Philips Ingenia CX 1.5 Tesla. Measurements will be performed in head first prone position and if not possible in head first supine position. Prone position is preferred because of less motion artefacts from respiration and aortic pulsation, less tendency of intestinal gas accumulation against the abdominal wall producing additional signal voids. Hence the differentiation with the hypointense mesh can be difficult.

There is no use of contrast material during the investigation. Preferably, the examination will be conducted in sober state i.e. patient should not eat for 2 hours before the examination. This is to reduce the risk of post prandial hyper-peristaltic.

DATA PROTECTION AND PRIVACY OF THE PATIENT All information about this study will be collected in the EuraHS Registry. The data will be entered into the EuraHS platform with a coded number, MOONCAT_01, MOONCAT_02, ...

Study Design

Study Type:
Observational
Anticipated Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective MRI Follow-up After Retromuscular Incisional Hernia Repair Using the Dynamesh CICAT Visible® Mesh
Study Start Date :
May 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Outcome Measures

Primary Outcome Measures

  1. visualization of the mesh surface [1 month]

    Clear visualization of the CICAT® prosthesis at 1 month postoperatively with MRI

Secondary Outcome Measures

  1. calculation of the mesh surface [up to 13 months]

    Calculation of mesh surface in comparison and % difference at 13 months postoperatively with MRI.

  2. visualization of the mesh surface [up to 13 months]

    Clear visualization of the CICAT® prosthesis up to 13 months postoperatively with MRI

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients scheduled for an retromusculare repair of an incisional hernia
Exclusion Criteria:
  • <18 years

  • Emergency surgery (incarcerated hernia)

  • Clean-contaminated or contaminated procedures

  • ASA score> 4

  • Pregnancy

  • No patient Informed Consent

  • Life expectancy of less than 2 years

Contacts and Locations

Locations

Site City State Country Postal Code
1 AZ Maria Middelares Ghent Belgium 9000

Sponsors and Collaborators

  • Algemeen Ziekenhuis Maria Middelares
  • Duomed

Investigators

  • Principal Investigator: Filip Muysoms, MD. PhD, Algemeen Ziekenhuis Maria Middelares

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Filip Muysoms, Head of the Department of Surgery, Algemeen Ziekenhuis Maria Middelares
ClinicalTrials.gov Identifier:
NCT02460029
Other Study ID Numbers:
  • MoonCat Study
First Posted:
Jun 2, 2015
Last Update Posted:
Jan 20, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2021